TABLE 5.
Phase I summary of essential and categorical agreement across five laboratories for 30 Pseudomonas aeruginosa isolates using 2022 CLSI breakpoints b
| Antimicrobial agent | Total N isolates | Essential agreement (%) a | Categorical agreement (%) a | Major errors (N min–N max) | Very major errors (N min–N max) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STD | 30-All | 50-All | STD | 30-All | 50-All | N “S” | STD | 30-All | 50-All | N “R” | STD | 30-All | 50-All | ||
| Doripenem | 30 | 94 (2.8) | 94 (1.5) | 96 (1.5) | 80.7 (2.8) | 83.3 (5.3) | 83.3 (6.2) | 17 | 0–0 | 0–0 | 0–0 | 11 | 0–0 | 0–0 | 0–0 |
| Imipenem | 30 | 92.7 (4.3) | 94.7 (1.8) | 94.7 (3.8) | 86.7 (6.7) | 86.7 (2.4) | 86.0 (4.9) | 14 | 0–2 | 0–1 | 0–2 | 14 | 0–0 | 0–0 | 0–0 |
| Meropenem | 30 | 94 (4.3) | 90.0 (2.4) | 92.7 (2.8) | 82.7 (3.7) | 80.7 (9.2) | 79.3 (8) | 16 | 0–0 | 0–2 | 0–1 | 10 | 0–0 | 0–0 | 0–0 |
| Aztreonam | 30 | 98.7 (1.8) | 97.3 (2.8) | 97.3 (2.8) | 90 (2.4) | 89.3 (4.3) | 88.7 (5.1) | 14 | 0–1 | 0–1 | 0–1 | 15 | 0–1 | 0–1 | 0–0 |
| Ceftazidime | 30 | 97.3 (2.8) | 96 (1.5) | 97.3 (4.3) | 98 (3) | 96 (3.7) | 97.3 (1.5) | 14 | 0–0 | 0–0 | 0–0 | 15 | 0–0 | 0–0 | 0–0 |
| Cefepime | 30 | 98 (1.8) | 97.3 (1.5) | 98 (1.8) | 82.7 (4.9) | 81.3 (7.7) | 82.7 (2.8) | 14 | 0–0 | 0–0 | 0–0 | 11 | 0–0 | 0–0 | 0–0 |
| Ceftazidime/avibactam | 29 | 97.2 (3.8) | 96.6 (4.9) | 95.2 (4.6) | 95.9 (3.8) | 93.1 (4.2) | 92.4 (4.5) | 24 | 0–3 | 0–3 | 0–3 | 5 | 0–1 | 0–0 | 0–0 |
| Ceftolozane/tazobactam | 30 | 96 (3.7) | 96 (1.5) | 95.3 (3) | 95.3 (1.8) | 96.7 (0) | 95.3 (3) | 23 | 0–0 | 0–0 | 0–1 | 6 | 0–0 | 0–0 | 0–0 |
| Piperacillin/tazobactam | 30 | 96.7 (2.4) | 99.3 (1.5) | 94.7 (3) | 87.3 (1.5) | 89.3 (3.7) | 86.7 (2.4) | 15 | 0–0 | 0–0 | 0–1 | 10 | 0–0 | 0–0 | 0–0 |
| Ciprofloxacin | 30 | 99.3 (1.5) | 99.3 (1.5) | 100 (0) | 94.7 (3) | 95.3 (4.5) | 97.3 (2.8) | 7 | 0–0 | 0–0 | 0–0 | 22 | 0–1 | 0–0 | 0–0 |
| Levofloxacin | 30 | 99.3 (1.5) | 100 (0) | 100 (0) | 94.7 (4.5) | 96 (1.5) | 95.3 (1.8) | 5 | 0–0 | 0–0 | 0–0 | 21 | 0–0 | 0–0 | 0–0 |
| Gentamicin | 30 | 98.7 (1.8) | 98.7 (1.8) | 99.3 (1.5) | 95.3 (3) | 97.3 (2.8) | 91.3 (4.5) | 17 | 0–0 | 0–0 | 0–0 | 9 | 0–0 | 0–0 | 0–0 |
| Tobramycin | 30 | 99.3 (1.5) | 100 (0) | 99.3 (1.5) | 99.3 (1.5) | 100 (0) | 99.3 (1.5) | 20 | 0–0 | 0–0 | 0–0 | 10 | 0–0 | 0–0 | 0–0 |
| Amikacin | 30 | 100 (0) | 97.3 (4.5) | 99.3 (1.5) | 98.6 (1.9) | 99.3 (1.5) | 100 (0) | 22 | 0–0 | 0–0 | 0–0 | 6 | 0–0 | 0–0 | 0–0 |
a
Mean (standard deviation).
b
STD, standard inoculum method, 10 µL transfer volume (TV); 30-All, 30 µL TV; 50-All, 50 µL TV. Bold indicates percent where the mean EA or CA was <90%.